Clinical trial: vitamin D3 treatment in Crohn’s disease – a randomized double‐blind placebo‐controlled study

Jørgensen, Søren Peter; Agnholt, Jørgen; Glerup, Henning; Lyhne, S.; Villadsen, Gerda Elisabeth; Hvas, Christian Lodberg; Bartels, Lars Erik; Kelsen, Jens; Christensen, Lisbet Ambrosius; Dahlerup, Jens Frederik

doi:10.1111/j.1365-2036.2010.04355.x

Cited by 334 publications

(285 citation statements)

References 23 publications

Supporting

Mentioning

259

Contrasting

Unclassified

Order By: Relevance

“…In pharmaceutical trials, the placebo group is typically unexposed to the therapeutic intervention, whereas in vitamin D clinical trials the placebo group have an existing background level of vitamin D, which may vary in participants. Both Jorgensen et al (14) and Raftery et al (50) reported a good baseline 25(OH)D level at study enrolment (69 nmol/l for both studies). It is plausible that supplementation in a vitamin-D-deficient CD group would be of greater benefit compared with a replete group.…”

Section: Vitamin D Status and Associations With Disease Severity In Cmentioning

confidence: 91%

“…There is new interest, however, in vitamin D in IBD 'beyond bone' as a treatment for the core inflammatory disease. Growing evidence from epidemiological studies, animal models, cross-sectional studies and some intervention studies appear to support such a role (11)(12)(13)(14)(15) . The aim of this review is to critically evaluate several strands of scientific evidence surrounding vitamin D and inflammation in autoimmune diseases, primarily focusing on IBD and to understand how this translates to disease management.…”

Section: Proceedings Of the Nutrition Societymentioning

confidence: 99%

“…In the context of CD, a target 25(OH)D concentration deemed optimal for antiinflammatory or therapeutic effects, if any, is not known. In the few RCTs of vitamin D in CD conducted to date (Table 2) (14) . Preliminary findings from our pilot intervention study showed that 50 μg (2000 IU)/d vitamin D raised levels from 69 to 92 nmol/l at 3 months, which was accompanied by a modest reduction in CRP but only in participants who achieved serum 25(OH)D >75 nmol/l (50) .…”

Section: Vitamin D Status and Associations With Disease Severity In Cmentioning

confidence: 99%

See 2 more Smart Citations

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

O’Sullivan

2014

Proc. Nutr. Soc.

View full text Add to dashboard Cite

There is increasing scientific interest in the field of vitamin D research, moving the focus beyond bone health to other disease processes. Low circulating vitamin D levels have been reported as a risk factor for several pathophysiologically divergent diseases, including cancers, diabetes, CVD, multiple sclerosis and inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). But, therein, remains the challenge: can any single nutrient contribute to multiple complex disease mechanisms and, ultimately, have therapeutic potential? The aim of this review is to critically evaluate several strands of scientific evidence surrounding vitamin D and inflammation, primarily focusing on IBD. Epidemiological studies suggest an increased incidence of IBD and rheumatoid arthritis in countries of more northern latitudes, mirroring sunlight patterns. A considerable body of evidence supports the anti-inflammatory effects of vitamin D, at least in animal models of IBD. Although it is accepted that suboptimal vitamin D status is common in IBD, some studies suggest that this associates with more severe disease. With regard to treatment, the data are only beginning to emerge from randomised controlled trials to suggest that people with IBD may remain in remission longer when treated with oral vitamin D. In conclusion, several strands of evidence suggest that vitamin D may modify the immune response in IBD. There is a continued need for large well-designed clinical trials and mechanistic studies to determine if, and how, this emerging promise translates into tangible clinical benefits for people with chronic debilitating diseases such as IBD.

show abstract

Section: Vitamin D Status and Associations With Disease Severity In Cmentioning

confidence: 91%

Section: Proceedings Of the Nutrition Societymentioning

confidence: 99%

Section: Vitamin D Status and Associations With Disease Severity In Cmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

O’Sullivan

2014

Proc. Nutr. Soc.

View full text Add to dashboard Cite

show abstract

“…For some medication regimens in IBD therapy, especially cortisone administration [45], an increased vitamin D and calcium supply is recommended to avoid demineralizing effects on bones. Studies showed a lower risk for clinical relapse as well as a decreased necessity for surgery in patients with Crohn's disease under treatment with Vitamin D [46,47]. Thus, a regular monitoring of vitamin D levels, especially in IBD patients with cortisone therapy, is important to prevent secondary diseases and to improve disease outcome.…”

Section: Food Group Hc Total Ibd Ibd (Intake In [G/d]) CD Ucmentioning

confidence: 99%

Dietary Habits and Nutrient Intake in Patients with Inflammatory Bowel Disease

Schink¹,

Mirsch²,

Dieterich³

et al. 2017

J Nutr Food Sci

View full text Add to dashboard Cite

Patients with inflammatory bowel diseases (IBD) are often affected by nutrient deficiencies. Besides a limited nutrient intake by disease-related side effects and malabsorption, the influence of diets and dietary changes is much discussed. However, data about food patterns are mostly based on subjective declarations. Therefore, this study aimed to achieve a detailed and objective analysis of nutrient intake and individual food habits in IBD, a prerequisite for an appropriate nutritional intervention in risk patients. One hundred IBD patients (n=70 Crohn's disease (CD), n=30 ulcerative colitis (UC)) and 30 healthy controls (HC) were included in the study. All participants filled in a disease-related and food frequency questionnaire. Fifteen healthy controls and 71 IBD patients additionally completed a questionnaire for self-imposed food restrictions. Most IBD patients and healthy controls showed a normal body mass index. However, within the IBD group, UC patients were more often overweight than CD patients (p=0.007). Food restrictions were common in all participants, but significantly more IBD patients restricted their consumption of fast food (p=0.037), fruits and vegetables (p=0.019). Especially CD patients with acute relapse consumed less fruits and vegetables (p=0.035). Contrary to subjective assessment, an objective survey of dietary intake revealed a significantly higher sugar intake of IBD patients compared to healthy controls (p<0.001) with an increased ingestion of sugar/confectionery (p=0.041), soft/isotonic drinks (p<0.001) and fruit/vegetable juices (p=0.022). Additionally, IBD patients ingested higher amounts of salt than healthy controls (p=0.005). Both groups showed an insufficient ingestion of folate, vitamin D and pantothenic acid.In conclusion, self-managed food restrictions appear to be common in IBD patients. The huge discrepancy between the subjective view of dietary habits and objective evaluation of nutrient intake indicates that nutrient assessment should be based on objective tools. A repetitive professional nutritional counseling is recommended to prevent and treat nutritional deficiencies.

show abstract

“…Despite this vitamin D insufficiency remains common. With the discovery of the vitamin D receptor (VDR) in numerous tissues throughout the body beyond bone, including immune cells, a strong interest in understanding the role of vitamin D in disease pathogenesis and as a possible therapy in Crohn's disease has emerged (12)(13)(14)(15) . The aim of the present review is to discuss vitamin D insufficiency in Crohn's disease, the potential benefits of supplementation and possible serum levels required to achieve the same.…”

mentioning

confidence: 99%

Optimal vitamin D levels in Crohn's disease: a review

Raftery

O’Sullivan

2014

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Vitamin D deficiency is common among patients with Crohn's disease. Serum 25-hydroxyvitamin D (25(OH)D) is the best measure of an individual's vitamin D status and current cut-off ranges for sufficiency are debatable. Several factors contribute to vitamin D deficiency in Crohn's disease. These include inadequate exposure to sunlight, inadequate dietary intake, impaired conversion of vitamin D to its active metabolite, increased catabolism, increased excretion and genetic variants in vitamin D hydroxylation and transport. The effects of low 25(OH)D on outcomes other than bone health are understudied in Crohn's disease. The aim of the present review is to discuss the potential roles of vitamin D and the possible levels required to achieve them. Emerging evidence suggests that vitamin D may have roles in innate and adaptive immunity, in the immune-pathogenesis of Crohn's disease, prevention of Crohn's disease-related hospitalisations and surgery, in reducing disease severity and in colon cancer prevention. The present literature appears to suggest that 25(OH)D concentrations of ≥75 nmol/l may be required for non-skeletal effects; however, further research on optimal levels is required.

show abstract

Clinical trial: vitamin D3 treatment in Crohn’s disease – a randomized double‐blind placebo‐controlled study

Abstract: SUMMARY BackgroundVitamin D has immune-regulatory functions in experimental colitis, and low vitamin D levels are present in Crohn's disease.

Cited by 334 publications

References 23 publications

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

Dietary Habits and Nutrient Intake in Patients with Inflammatory Bowel Disease

Optimal vitamin D levels in Crohn's disease: a review

Contact Info

Product

Resources

About